Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to $523254.0.

  • Cartesian Therapeutics' Treasury Shares rose 1674.28% to $523254.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $523254.0, marking a year-over-year increase of 1674.28%. This contributed to the annual value of $444238.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Cartesian Therapeutics' Treasury Shares stood at $523254.0, which was up 1674.28% from $533331.0 recorded in Q2 2025.
  • Cartesian Therapeutics' Treasury Shares' 5-year high stood at $2.5 million during Q1 2023, with a 5-year trough of $394450.0 in Q4 2021.
  • Its 5-year average for Treasury Shares is $1.0 million, with a median of $567246.5 in 2021.
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 47080.4% in 2021, then plummeted by 8115.69% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Treasury Shares (Quarter) stood at $394450.0 in 2021, then soared by 332.39% to $1.7 million in 2022, then increased by 20.37% to $2.1 million in 2023, then crashed by 78.36% to $444238.0 in 2024, then increased by 17.79% to $523254.0 in 2025.
  • Its last three reported values are $523254.0 in Q3 2025, $533331.0 for Q2 2025, and $572605.0 during Q1 2025.